Skip to main content

Table 2 Limitations of peptide vaccines

From: Progress and controversies in developing cancer vaccines

• Limited by MHC restriction.
• Unique individual tumor-specific antigens difficult to include.
• Rapid degradation in vivo.
• Heterogeneity of tumor antigen expression.
• Ignorance. We don't yet know how best to vaccinate with them. *
• Clinical responses have been rare in most series (with peptide or any vaccine alone).*
  1. * The last two points apply equally to practically all T cell vaccines, not just peptide vaccines.